SequelSEC

AtriCure, Inc. ATRC

Surgical & Medical Instruments & Apparatus · CIK 0001323885 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$569.62M
Fiscal year ended 2026-06-30
Operating income
$12.89M
Fiscal year ended 2026-06-30
Free cash flow
$53.11M
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$1.57BMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$31.55Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue2.9×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity3.2×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Surgical & Medical Instruments & Apparatus filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Long-term debt / equity0.13x19th
FCF margin9.0%78th
Gross margin75.0%77th
Net margin-2.1%71th
Operating margin-1.8%67th
CapEx / revenue1.7%38th
Current ratio3.96x60th
R&D / revenue18.6%56th
SBC / revenue8.4%55th
Revenue YoY growth14.9%52th

AtriCure, Inc. (ATRC) reported revenue of $569.62M and net income of $10.55M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from AtriCure, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Surgical & Medical Instruments & Apparatus.

Income

AtriCure, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$569.62M
Cost of revenue$135.01M
Gross profit$434.61M
Operating income$12.89M
Net income$10.55M
Research & development$98.03M
Weighted-average diluted sharesUnavailable
Pretax income$12.09M
Income tax expense$1.54M
Diluted EPSUnavailable
Selling, general & administrative$323.68M
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

AtriCure, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$167.79M
Total assets$676.64M
Current assets$345.53M
Total liabilities$160.21M
Current liabilities$81.92M
Total equity incl. NCI$516.43M
Temporary (mezzanine) equityUnavailable
Inventory$83.92M
Accounts receivable$79.98M
Goodwill$234.78M
Long-term debt$61.00M
Accounts payable$35.85M

Cash flow

AtriCure, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow$64.94M
Capital expenditures$11.82M
Investing cash flow-$12.82M
Financing cash flow-$1.91M
Net change in cash$49.99M
Stock-based compensation$47.27M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

AtriCure, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow$53.11M
Gross margin76.3%
Operating margin2.3%
FCF margin9.3%
SBC / revenue8.3%
Current ratio4.22x
Revenue YoY growth13.9%
Net margin1.9%
R&D / revenue17.2%
CapEx / revenue2.1%
Long-term debt / equity0.12x
Effective tax rate12.8%

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ATRC in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-07-27View SEC filing
10-Q · Filed 2026-05-06View SEC filing
10-K · Filed 2026-02-19View SEC filing
10-Q · Filed 2025-10-30View SEC filing
10-Q · Filed 2025-07-30View SEC filing
10-Q · Filed 2025-04-30View SEC filing

Companies in the same industry

ADGM AEMD ALUR AMIX ANGO ANIK AORT APYX ARAY ATEC AURX BAX

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.